v3.26.1
INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS (Tables)
12 Months Ended
Dec. 31, 2025
INVESTMENT IN EQUITY SECURITIES, AT FAIR VALUE AND LONG-TERM INVESTMENTS  
Schedule of investments in equity securities

Gross

(In thousands)

unrealized

Aggregate fair

As of December 31, 2024

  ​ ​ ​

Cost

  ​ ​ ​

losses

  ​ ​ ​

value

BioInvent International AB - ordinary shares

$

2,723

$

(166)

$

2,557

BioInvent International AB - warrants

656

(590)

66

Total

3,379

(756)

$

2,623

Schedule of components of long-term investments

Gross

Gross

unrealized

As of December 31, 2025 and 2024

unrealized

losses (including

Carrying

(In thousands)

  ​ ​ ​

Cost

  ​ ​ ​

gains

  ​ ​ ​

impairment)

  ​ ​ ​

amount

Investments in equity securities using measurement alternative

 

  ​

 

  ​

 

  ​

 

Alesta Therapeutics B.V. - series A preferred shares

$

331

$

$

$

331

Alesta Therapeutics B.V. - ordinary shares

 

2,250

 

 

(865)

 

1,385

Total

$

2,581

$

$

(865)

$

1,716